Presentation is loading. Please wait.

Presentation is loading. Please wait.

The IASLC Lung Cancer Database Summary of Cases Contributed to Project Total cases submitted 100,869 Excluded from analyses Excluded from analyses19,854.

Published byKolby Nutley Modified over 9 years ago

Similar presentations

Presentation on theme: "The IASLC Lung Cancer Database Summary of Cases Contributed to Project Total cases submitted 100,869 Excluded from analyses Excluded from analyses19,854."— Presentation transcript:

1 The IASLC Lung Cancer Database Summary of Cases Contributed to Project Total cases submitted 100,869 Excluded from analyses Excluded from analyses19,854 Outside of 1990-2000 time frame Outside of 1990-2000 time frame5,443 Incomplete survival data Incomplete survival data1,505 Unknown histology Unknown histology2,468 Incomplete stage information Incomplete stage information7,720 Recurrent cases and other exclusions Recurrent cases and other exclusions1,603 Carcinoids, sarcomas and other histologies Carcinoids, sarcomas and other histologies1,115 Included in analyses 81,015 Small Cell Lung Cancer (and mixed SCLC/NSCLC)Small Cell Lung Cancer (and mixed SCLC/NSCLC)13,290 Non-Small Cell Lung CancerNon-Small Cell Lung Cancer67,725 Updated from: Goldstraw P, Crowley JJ. The International Association for the Study of Lung Cancer International staging project on lung cancer. J Thorac Oncol 2006; 1: 281-286.

2 The IASLC Lung Cancer Database Treatment Modalities 81,495 Cases Surgery36% Chemotherapy21%RT11% Surgery + Chemo 4% Surgery + RT 4% Chemo 12% Surgery + Chemo + RT 3% No treatment details or best supportive care: 10% From: Goldstraw P, Crowley JJ. The International Association for the Study of Lung Cancer International staging project on lung cancer. J Thorac Oncol 2006; 1: 281-286.

3 The IASLC Lung Cancer Database Types of Contributing Groups 81,495 Cases

4 The IASLC Lung Cancer Database Stage Distribution, Non-small Cell Lung Cancer 67,725 Cases with Clinical Stage, Pathological Stage, or Both

5 The IASLC Lung Cancer Database Clinical Stage Distribution by Continent, Non-small Cell Lung Cancer 53,646 Cases 58% 7%21%14% Percent of total cases contributed with clinical stage From: Goldstraw P, Crowley JJ. The International Association for the Study of Lung Cancer International staging project on lung cancer. J Thorac Oncol 2006; 1: 281-286.

6 The IASLC Lung Cancer Database Pathological Stage Distribution by Continent, Non-small Cell Lung Cancer 33,933 Cases Percent of total cases contributed with pathologic stage 51%7%13%28%

7 The IASLC Lung Cancer Database Stage Distribution by Continent, Small Cell Lung Cancer 13,290 Cases (58%) (6%) (34%)(2%) Percent of total small cell cases contributed From: Goldstraw P, Crowley JJ. The International Association for the Study of Lung Cancer International staging project on lung cancer. J Thorac Oncol 2006; 1: 281-286.

8 T-Descriptors – Size of Primary Tumor “Best Split” for Tumor Size, pT1 Cases From: Rami-Porta R, Ball D, Crowley J et al. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2: 593-602.

9 T-Descriptors – Size of Primary Tumor “Best Split” for Tumor Size, pT2 Cases 7.3 cm From: Rami-Porta R, Ball D, Crowley J et al. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2: 593-602

10 Size of Primary Tumor, pT1-3, N0 NSCLC T-Descriptors – Size of Primary Tumor From: Rami-Porta R, Ball D, Crowley J et al. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2: 593-602

11 Size of Primary Tumor, cT1-3, N0 NSCLC T-Descriptors – Size of Primary Tumor From: Rami-Porta R, Ball D, Crowley J et al. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2: 593-602.

12 T-Descriptors - Validation Size of Primary Tumor T1-3 N0 NSCLC United States National Cancer Institute SEER Registries From: Groome PA, Bolejack V, Crowley JJ et al. The IASLC lung cancer project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 694-705

13 Pathological T3/T4 – M1 NSCLC T-Descriptors – Additional Nodules and Pleural Dissemination From: Rami-Porta R, Ball D, Crowley J et al. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2: 593-602.

14 T-Descriptors – Additional Nodules and Pleural Dissemination Clinical T3/T4 – M1 NSCLC From: Rami-Porta R, Ball D, Crowley J et al. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2: 593-602.

15 T-Descriptors - Validation Additional Nodules and Pleural Dissemination, T3/4-M1 NSCLC United States National Cancer Institute SEER Registries From: Groome PA, Bolejack V, Crowley JJ et al. The IASLC lung cancer project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 694-705

16 N-Descriptors Clinical N-stage, cN0-cN3 From: Rusch VW, Crowley J, Giroux DJ et al. The IASLC lung cancer project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2: 603-612

17 N-Descriptors Surgically Managed Patients From: Rusch VW, Crowley J, Giroux DJ et al. The IASLC lung cancer project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2: 603-612

18 N-Descriptors - Validation N-Stage N0-N3, M0 NSCLC United States National Cancer Institute SEER Registries From: Groome PA, Bolejack V, Crowley JJ et al. The IASLC lung cancer project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 694-705

19 N-Descriptors: Nodal Zones Shown in: Rusch VW, Crowley J, Giroux DJ et al. The IASLC lung cancer project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2: 603-612. Copyright Memorial Sloan-Kettering Cancer Center. Used with permission.

20 N-Descriptors N-Status and Number of Involved N-Zones From: Rusch VW, Crowley J, Giroux DJ et al. The IASLC lung cancer project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2: 603-612

21 M-Descriptors Clinically Staged T4 and M1 Descriptors From: Postmus PE, Brambilla E, Chansky K et al. The IASLC lung cancer project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007; 2: 686-693

22 M-Descriptors Best* Stage T4 and M1 Descriptors *Best Stage = Path stage if available, otherwise clinical From: Postmus PE, Brambilla E, Chansky K et al. The IASLC lung cancer project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007; 2: 686-693

23 M-Descriptors - Validation T4 and M1 Descriptors United States National Cancer Institute SEER Registries From: Postmus PE, Brambilla E, Chansky K et al. The IASLC lung cancer project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007; 2: 686-693

24 TNM Stage Category RPA Output for Analysis of TNM Stage Groupings From: Goldstraw P, Crowley J, Chansky K et al. The IASLC lung cancer project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714

25 TNM Stage Category Clinical TNM Stage v. 6 and Proposed v. 7 cTNM 6 th Edition cTNM 7 th Edition From: Goldstraw P, Crowley J, Chansky K et al. The IASLC lung cancer project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714

26 TNM Stage Category Pathological Stage v. 6 and Proposed v. 7 pTNM 6 th Edition pTNM 7 th Edition From: Goldstraw P, Crowley J, Chansky K et al. The IASLC lung cancer project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714

27 TNM Stage Category - Validation TNM Stage v. 6 and Proposed v. 7 United States National Cancer Institute SEER Registries TNM 6 th Edition TNM 7 th Edition From: Groome PA, Bolejack V, Crowley JJ et al. The IASLC lung cancer project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 694-705

Download ppt "The IASLC Lung Cancer Database Summary of Cases Contributed to Project Total cases submitted 100,869 Excluded from analyses Excluded from analyses19,854."

Similar presentations

Small Cell Lung Cancer Clinical T-Stage, N0-N3 M0 SCLC From: Shepherd FA, Crowley J, Van Houtte P et al. The IASLC lung cancer staging project: proposals.

Small Cell Lung Cancer Clinical T-Stage, N0-N3 M0 SCLC From: Shepherd FA, Crowley J, Van Houtte P et al. The IASLC lung cancer staging project: proposals.
Jaime Palomino, MD Pulmonary, Critical Care Medicine Tulane University.

Jaime Palomino, MD Pulmonary, Critical Care Medicine Tulane University.
Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.

Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.
Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.

Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.
AJCC Staging Moments AJCC TNM Staging 7th Edition Lung Case #3 Contributors: Valerie W. Rusch, MD Memorial Sloan-Kettering Cancer Center, New York, New.

AJCC Staging Moments AJCC TNM Staging 7th Edition Lung Case #3 Contributors: Valerie W. Rusch, MD Memorial Sloan-Kettering Cancer Center, New York, New.
AJCC Staging Moments AJCC TNM Staging 7th Edition Lung Case #1 Contributors: Valerie W. Rusch, MD Memorial Sloan-Kettering Cancer Center, New York, New.

AJCC Staging Moments AJCC TNM Staging 7th Edition Lung Case #1 Contributors: Valerie W. Rusch, MD Memorial Sloan-Kettering Cancer Center, New York, New.
SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne.

SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne.
강 창 현 서울대학교병원 흉부외과 서울대학교 의과대학. Staging Communication Evaluation TreatmentPrognosis Research.

강 창 현 서울대학교병원 흉부외과 서울대학교 의과대학. Staging Communication Evaluation TreatmentPrognosis Research.
Multimodality therapy for locally advanced thymomas: a cohort study of prognostic factors from a European multicentric database Dr. GIOVANNI LEUZZI Department.

Multimodality therapy for locally advanced thymomas: a cohort study of prognostic factors from a European multicentric database Dr. GIOVANNI LEUZZI Department.
Malignant Pleural Effusion (M.P.E.)

Malignant Pleural Effusion (M.P.E.)
Postoperative Radiotherapy for Patients with Stage II or III Nonsmall Cell Lung Cancer treated with Sublobar Resections: A SEER Registry Analysis Scott.

Postoperative Radiotherapy for Patients with Stage II or III Nonsmall Cell Lung Cancer treated with Sublobar Resections: A SEER Registry Analysis Scott.
First author: Roman Adina Co-author: Andone Sebastian

First author: Roman Adina Co-author: Andone Sebastian
Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,

Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,
Development of Lung Cancer Staging Steven M. Keller, M.D. Director Thoracic Surgery, Weiler Hospital Professor of Cardiothoracic Surgery Albert Einstein.

Development of Lung Cancer Staging Steven M. Keller, M.D. Director Thoracic Surgery, Weiler Hospital Professor of Cardiothoracic Surgery Albert Einstein.
“Validation” of the Proposed IASLC/ITMIG Staging Revisions of Thymic Carcinomas Using Data from 287 Patients Yang Zhao; Heng Zhao Division of Thoracic.

“Validation” of the Proposed IASLC/ITMIG Staging Revisions of Thymic Carcinomas Using Data from 287 Patients Yang Zhao; Heng Zhao Division of Thoracic.
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl,

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl,
Evidence Based Approach 5-Year Survival Rate for Breast Cancer Stage IV is 14% 2 to 5 percent become long-term survivors, possibly cured of their disease.

Evidence Based Approach 5-Year Survival Rate for Breast Cancer Stage IV is 14% 2 to 5 percent become long-term survivors, possibly cured of their disease.
Joan Schiller, MD Professor of Medicine Chief, Division of Hematology/Oncology University of Texas Southwestern Medical Center Deputy Director Simmons.

Joan Schiller, MD Professor of Medicine Chief, Division of Hematology/Oncology University of Texas Southwestern Medical Center Deputy Director Simmons.
Non-small cell lung cancer Lancet 2011;378:1727-40 Peter Goldstraw, David Ball, James R Jett, Thierry Le Chevalier, Eric Lim, Andrew G Nicholson, Frances.

Non-small cell lung cancer Lancet 2011;378: Peter Goldstraw, David Ball, James R Jett, Thierry Le Chevalier, Eric Lim, Andrew G Nicholson, Frances.
2016 Edits.

2016 Edits.

Similar presentations

Ads by Google